Skip to main content
. 2020 Sep 14;7:117–131. doi: 10.2147/JHC.S248314

Table 8.

Pertinent AEs by Treatment

Pertinent AEs TARE_alone TARE_sorafenib TARE_alternative
Grade 1–2 Grade 3–4 Grade 1–2 Grade 3–4 Grade 1–2 Grade 3–4
Constitutional symptoms
 Fever 4 (6.1) 0 2 (2.5) 0 1 (3.2) 0
 Fatigue 33 (50.0) 0 44 (55.7) 0 13 (41.9) 0
 Weight loss 2 (3.0) 0 3 (3.8) 0 1 (3.2) 0
 Loss of appetite 3 (4.5) 0 9 (11.4) 0 2 (6.5) 0
 Dermatological 1 (1.5) 0 19 (24.1) 2 (2.5) 1 (3.2) 0
Gastrointestinal disorders
 Diarrhea 0 0 15 (19.0) 0 0 0
 Nausea or vomiting 14 (21.2) 0 34 (43.0) 0 9 (29.1) 0
 Abdominal discomfort 10 (15.1) 3 (4.5) 29 (36.7) 1 (1.3) 11 (35.5) 0
 Anorexia 3 (4.5) 0 6 (7.6) 0 1 (3.2) 0
 Constipation 2 (3.0) 0 5 (6.3) 0 0 0
 Gastroesophageal varices hemorrhage 0 0 0 2 (2.5) 0 1 (3.2)
 Gastritis 0 0 1 (1.3) 0 0 1 (3.2)
 Pancreatitis 0 1 (1.5) 0 0 0 0
 Cholecystitis 0 0 0 0 0 1 (3.2)
 Intra-abdominal bleeding 0 1 (1.5) 0 1 (1.3) 0 0
Liver disorders
 Ascites 4 (6.1) 4 (6.1) 6 (7.6) 2 (2.5) 4 (12.9) 2 (6.5)
 REILD 0 0 0 0 0 0
 Hepatic encephalopathy 0 3 (4.5) 0 2 (2.5) 0 0
Respiratory symptoms
 Dyspnea 4 (6.1) 1 (1.5) 4 (5.1) 0 3 (9.7) 0
 Cough 1 (1.5) 0 0 0 0 0
 Pleural effusion 0 0 0 1 (1.3)
 Radiation-induced pneumonitis 0 0 0 0 0 0
Laboratory abnormalities
 Hyperbilirubinemia 13 (19.7) 3 (4.5) 24 (30.4) 1 (1.3) 7 (22.6) 0
 Hypoalbuminemia 10 (15.1) 0 19 (24.1) 0 6 (19.3) 0
 Anemia 5 (7.5) 0 11 (13.9) 0 6 (19.3) 1 (3.2)
 Thrombocytopenia 12 (18.2) 0 17 (21.5) 3 (3.8) 10 (32.3) 0
 Leukopenia 11 (16.7) 2 (3.0) 13 (16.4) 3 (3.8) 5 (16.1) 0
 Renal dysfunction 0 0 2 (2.5) 0 0 0
 Increased AST 4 (6.0) 0 8 (10.1) 0 4 (12.9) 0
 Increased ALT 2 (3.0) 0 2 (2.5) 1 (1.3) 3 (9.7) 0
 Increased ALP 1 (1.5) 0 7 (8.9) 0 2 (6.5) 0
Other
 Electrolyte imbalance 0 1 (1.5) 2 (2.5) 0 0 0
 Sepsis 0 1 (1.5) 0 2 (2.5) 0 0

Abbreviations: AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase.